J 2012

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

PAVLÍK, Tomáš; Ondřej MÁJEK; Jan MUŽÍK; Jana KOPTÍKOVÁ; Lubomír SLAVÍČEK et al.

Základní údaje

Originální název

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

Autoři

PAVLÍK, Tomáš; Ondřej MÁJEK ORCID; Jan MUŽÍK; Jana KOPTÍKOVÁ; Lubomír SLAVÍČEK; Jindřich FÍNEK; David FELTL; Rostislav VYZULA a Ladislav DUŠEK

Vydání

BMC Public Health, 2012, 1471-2458

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.076

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00057270

Organizační jednotka

Lékařská fakulta

UT WoS

000302376800001

Klíčová slova anglicky

PREOPERATIVE RADIOTHERAPY; PREVALENCE; POPULATION; CARE; PATTERNS; FRANCE; STAGE; PROJECTIONS; PREDICTION; RECURRENCE

Příznaky

Mezinárodní význam
Změněno: 18. 6. 2012 09:26, Mgr. Michal Petr

Anotace

V originále

Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic, introducing a need for a prospective modelling of the incidence and prevalence rates. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources. Methods This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015. Results Several scenarios are adopted to cover the plausible development of the incidence and survival rates, and the probability of an anti-tumour therapy initiation. Based on the scenarios, the model predicts an increase in CRC prevalence from 13% to 30% in comparison with the situation in 2008. Moreover, the model predicts that 10,074 to 11,440 CRC patients will be indicated for anti-tumour therapy in the Czech Republic in 2015. Considering all patients with terminal cancer recurrence and all patients primarily diagnosed in stage IV, it is predicted that 3,485 to 4,469 CRC patients will be treated for the metastatic disease in 2015, which accounts for more than one third (34-40%) of all CRC patients treated this year. Conclusions A new model for the estimation of the number of CRC patients requiring active anti-tumour therapy is proposed in this paper. The model respects the clinical stage as the primary stratification factor and utilizes solely the population-based cancer registry data. Thus, no specific hospital data records are needed in the proposed approach. Regarding the short-term prediction of the CRC burden in the Czech Republic, the model confirms a continuous increase in the burden that must be accounted for in the future planning of health care in the Czech Republic.

Návaznosti

GD102/09/H083, projekt VaV
Název: Informační technologie v biomedicínském inženýrství
Investor: Grantová agentura ČR, Informační technologie v biomedicínckém inženýrství
NS10650, projekt VaV
Název: Výzkum metod standardizace zdravotní péče zaměřený na vývoj národní sady standardů zdravotních služeb
Investor: Ministerstvo zdravotnictví ČR, Výzkum metod standardizace zdravotní péče zaměřený na vývoj národní sady standardů zdravotních služeb